View More Recent Stories

Oct 17, 2019 05:00AM Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
Oct 10, 2019 08:41AM Myovant Sciences (MYOV) Reports Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results
Oct 10, 2019 08:30AM Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
Sep 6, 2019 03:01AM Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
Sep 6, 2019 03:01AM Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
Aug 27, 2019 01:26PM CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
Aug 27, 2019 08:30AM Myovant Sciences to Participate in Upcoming September Investor Conferences
Aug 20, 2019 08:34AM Myovant Sciences (MYOV) Completes SPIRIT 2 Study Recruitment
Aug 20, 2019 08:30AM Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Aug 20, 2019 08:30AM Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Aug 6, 2019 04:05PM Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
Jul 23, 2019 07:37AM Myovant Sciences (MYOV) Reports Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy
Jul 23, 2019 07:30AM Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
Jul 23, 2019 07:30AM Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
Jul 22, 2019 04:01PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Wo
Jul 22, 2019 04:01PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Wo
Jul 10, 2019 08:30AM Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
May 24, 2019 04:05PM Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
May 14, 2019 07:33AM Myovant Sciences (MYOV) Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 14, 2019 07:30AM Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 14, 2019 07:30AM Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 13, 2019 04:16PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in
May 13, 2019 04:16PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in
View More Recent Stories